Cost-effectiveness analysis of Daclatasvir/Sofosbuvir for the treatment of the HCV patients failed after the first line with second generation of DAAs in Italy .

Americo Cicchetti; Matteo Ruggeri; L. A. Kondili; C. Drago; F. De Solda; C. Nappi

doi:10.1080/14737167.2019.1537784

Cost-effectiveness analysis of Daclatasvir/Sofosbuvir for the treatment of the HCV patients failed after the first line with second generation of DAAs in Italy .

Americo Cicchetti, Matteo Ruggeri, L. A. Kondili, C. Drago, F. De Solda, C. Nappi

Risultato della ricerca: Contributo in rivista › Articolo in rivista

2 Citazioni (Scopus)

Abstract

E

Lingua originale	English
pagine (da-a)	363-374
Numero di pagine	12
Rivista	EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH
Volume	2019
DOI	https://doi.org/10.1080/14737167.2019.1537784
Stato di pubblicazione	Pubblicato - 2019

Keywords

Cost effectiveness

Accesso al documento

10.1080/14737167.2019.1537784

Altri file e collegamenti

Link a IRIS PubliCatt

Cita questo

Cicchetti, A., Ruggeri, M., Kondili, L. A., Drago, C., De Solda, F., & Nappi, C. (2019). Cost-effectiveness analysis of Daclatasvir/Sofosbuvir for the treatment of the HCV patients failed after the first line with second generation of DAAs in Italy . EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2019, 363-374. https://doi.org/10.1080/14737167.2019.1537784

@article{c7aac6bf813145ad807292365df053a8,

title = "Cost-effectiveness analysis of Daclatasvir/Sofosbuvir for the treatment of the HCV patients failed after the first line with second generation of DAAs in Italy .",

abstract = "E",

keywords = "Cost effectiveness, Cost effectiveness",

author = "Americo Cicchetti and Matteo Ruggeri and Kondili, {L. A.} and C. Drago and {De Solda}, F. and C. Nappi",

year = "2019",

doi = "10.1080/14737167.2019.1537784",

language = "English",

volume = "2019",

pages = "363--374",

journal = "Expert Review of Pharmacoeconomics and Outcomes Research",

issn = "1473-7167",

publisher = "-London : Expert Reviews Ltd, -London : Future Drugs, 2001-",

}

Cicchetti, A, Ruggeri, M, Kondili, LA, Drago, C, De Solda, F & Nappi, C 2019, 'Cost-effectiveness analysis of Daclatasvir/Sofosbuvir for the treatment of the HCV patients failed after the first line with second generation of DAAs in Italy .', EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, vol. 2019, pagg. 363-374. https://doi.org/10.1080/14737167.2019.1537784

Cost-effectiveness analysis of Daclatasvir/Sofosbuvir for the treatment of the HCV patients failed after the first line with second generation of DAAs in Italy . / Cicchetti, Americo; Ruggeri, Matteo; Kondili, L. A. et al.

In: EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, Vol. 2019, 2019, pag. 363-374.

Risultato della ricerca: Contributo in rivista › Articolo in rivista

TY - JOUR

T1 - Cost-effectiveness analysis of Daclatasvir/Sofosbuvir for the treatment of the HCV patients failed after the first line with second generation of DAAs in Italy .

AU - Cicchetti, Americo

AU - Ruggeri, Matteo

AU - Kondili, L. A.

AU - Drago, C.

AU - De Solda, F.

AU - Nappi, C.

PY - 2019

Y1 - 2019

N2 - E

AB - E

KW - Cost effectiveness

UR - http://hdl.handle.net/10807/135548

U2 - 10.1080/14737167.2019.1537784

DO - 10.1080/14737167.2019.1537784

M3 - Article

VL - 2019

SP - 363

EP - 374

JO - Expert Review of Pharmacoeconomics and Outcomes Research

JF - Expert Review of Pharmacoeconomics and Outcomes Research

SN - 1473-7167

ER -

Cost-effectiveness analysis of Daclatasvir/Sofosbuvir for the treatment of the HCV patients failed after the first line with second generation of DAAs in Italy .

Abstract

Keywords

Accesso al documento

Altri file e collegamenti

Fingerprint

Cita questo